Blum Ex Rel. Blum v. Merrell Dow Pharmaceuticals, Inc.

705 A.2d 1314, 1997 Pa. Super. LEXIS 3861
CourtSuperior Court of Pennsylvania
DecidedDecember 29, 1997
StatusPublished
Cited by54 cases

This text of 705 A.2d 1314 (Blum Ex Rel. Blum v. Merrell Dow Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Superior Court of Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Blum Ex Rel. Blum v. Merrell Dow Pharmaceuticals, Inc., 705 A.2d 1314, 1997 Pa. Super. LEXIS 3861 (Pa. Ct. App. 1997).

Opinion

BECK, Judge:

This is a pharmaceutical products liability action. Plaintiffs-appellees are Jeffrey Blum, a minor, and his parents and natural guardians Joan and Fred Blum. Jeffrey Blum was born with clubfeet. The Blums filed this action against defendant-appellant Merrell Dow Pharmaceuticals, Inc. (“Merrell Dow”), the manufacturer of the drug Bendectin. While pregnant with Jeffrey, Joan Blum took Bendectin, which was prescribed by her doctor to relieve pregnancy-related nausea. After trial in 1986, the jury returned a verdict in favor of the Blums, finding specifically that his mother’s ingestion of Bendectin during pregnancy caused Jeffrey Blum’s clubfeet. However, the verdict was ultimately vacated because it was rendered by only eleven jurors. Blum v. Merrell Dow Pharmaceuticals, Inc., 385 Pa.Super. 151, 560 A.2d 212 (1989), aff'd, 534 Pa. 97, 626 A.2d 537 (1993) (Blum I).

The matter was remanded for a new trial, which was held between May 5 and June 14, 1994, when the jury found in favor of the Blums, awarding $4 million in compensatory damages to Jeffrey Blum, $200,000 in compensatory damages to his parents, and $15 million in punitive damages. The court denied appellant’s motions for judgment notwithstanding the verdict (j.n.o.v.) or for a new trial, and molded the verdict to include delay damages for a total award of $24,111,-147. This timely appeal followed.

On appeal, Merrell Dow argues that the trial court should have entered j.n.o.v. in its favor because the Blums did not present sufficient admissible evidence of causation to hold Merrell Dow liable for Jeffrey Blum’s injuries. Merrell Dow further argues that, even if j.n.o.v. is not entered, it is entitled to a new trial because of several trial court errors, including: 1) the admission of incompetent expert testimony on the issue of causation; 2) permitting the jury to learn that Merrell Dow lost the first trial of this case; 3) instructing the jury on fraud despite the fact that there was no evidence of fraud; 4) instructing the jury on implied warranty of *1316 fitness for a particular purpose where no evidence of a particular purpose was shown and where there is no such cause of action in a prescription drug case; 5) instructing the jury on express warranty where a breach was not shown; and 6) instructing the jury on punitive damages where Merrell Dow’s conduct was neither outrageous nor reckless and where the award of punitive damages in this case violates the United States Constitution. After our exhaustive review of the complex arguments and extensive record, we reluctantly reverse and remand with instructions to the trial court to enter j.n.o.v. in favor of Merrell Dow.

Standard of Review

Faced with a motion for j.n.o.v., the court must decide whether, viewing the evidence in the light most favorable to the verdict winner, there was sufficient evidence to sustain the verdict; if there was, j.n.o.v. should not be granted. Sheely v. Beard, 696 A.2d 214 (Pa.Super.1997); Gray v. H.C. Duke & Sons, Inc., 387 Pa.Super. 95, 563 A.2d 1201 (1989). We hold that the trial judge abused his discretion in allowing certain scientific expert testimony on causation to be admitted at trial. In the absence of this causation evidence, judgment should have been entered in favor of Merrell Dow as a matter of law. We therefore reverse the trial court’s order denying judgment’ n.o.v. We need not reach appellant’s other issues on appeal.

Plaintiffs Must Prove Causation

In any tort action based on a theory of negligence or products liability, the plaintiff is required to prove by a preponderance of the evidence that the defendant’s conduct was the proximate cause of the plaintiffs damage. Sherk v. Daisy-Heddon, 498 Pa. 594, 450 A.2d 615 (1982); Christian v. Pennsylvania Financial Responsibility Assigned Claims Plan, 454 Pa.Super. 512, 686 A.2d 1 (1996). The test for proximate causation is whether the defendant’s acts or omissions were a substantial factor in bringing about the plaintiffs harm. First v. Zem Zem Temple, 454 Pa.Super. 548, 686 A.2d 18 (1996). In this ease, the Blums were required to prove that Joan Blum’s ingestion of Bendectin during her pregnancy was the proximate cause of her son’s injuries. This general causation issue involves two underlying questions: 1) Does the drug Bendectin cause birth defects such as clubfeet? and 2) Did Bendectin cause Jeffrey Blum’s clubfeet?

It is extremely difficult to answer these basic questions. Birth defects occur in two to three percent of births regardless of exposure to Bendectin. Daubert v. Merrell Dow Pharmaceuticals, Inc., 43 F.3d 1311, 1313 (9th Cir.1995). Most birth defects occur for no known reason. Id. The causation evidence in this case, therefore, must necessarily come in the form of probabilities rather than certainties. Of course, circumstantial evidence may suffice to prove causation in a tort case, but it must establish by a preponderance of the evidence that the alleged cause was a substantial factor in bringing about the claimed effect. Finney v. G.C. Murphy Co., 406 Pa. 555, 178 A.2d 719 (1962) (plaintiff in tort case is not required to prove with mathematical exactness and caliper precision that an incident could only happen in one manner to the exclusion of all other possibilities).

In an effort to answer the critical causation question, the Blums proffered scientific expert testimony from several witnesses. Alan K. Done, M.D., and Adrian Gross, D.V.M., testified at the first trial, and their testimony was read to the jury during the second trial. In the second trial, Stuart Newman, Ph.D., testified via videotaped deposition. These witnesses offered their opinions that Bendec-tin is a human “teratogen” 1 while conceding that birth defects occur even in the absence of Bendectin exposure. Done, Gross and Newman all testified as to general causation, that is, the teratogenic potential of B endec-tin. Only Dr. Done opined more specifically that Bendectin caused Jeffrey Blum’s clubfeet.

An expert witness is qualified -to offer an opinion if he or she has sufficient skill, knowledge, or experience in a field or calling as to make it appear that his or her *1317 opinion or inference will probably aid the trier in its search for truth. Dambacher v. Mallis, 336 Pa.Super. 22, 485 A.2d 408 (1984). To be admissible, expert evidence on scientific matters must pass through an additional hoop.

The Frye Test

Our law is well established that the trial court enjoys broad discretion in admitting or excluding evidence.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

City of Philadelphia v. J. Healey (WCAB)
Commonwealth Court of Pennsylvania, 2023
Walsh v. BASF Corporation Apl of: Syngenta
Supreme Court of Pennsylvania, 2020
Walsh v. BASF Corporation Apl of: Monsanto
Supreme Court of Pennsylvania, 2020
Walsh v. BASF Corporation Apl of: Dow
Supreme Court of Pennsylvania, 2020
Walsh v. BASF Corporation Apl of: Deere
Supreme Court of Pennsylvania, 2020
Walsh v. BASF Corporation Apl of: BASF
Supreme Court of Pennsylvania, 2020
Bristol Borough v. Workers' Comp. Appeal Bd.
206 A.3d 585 (Commonwealth Court of Pennsylvania, 2019)
City of Phila. v. Workers' Comp. Appeal Bd.
195 A.3d 197 (Supreme Court of Pennsylvania, 2018)
Com. v. Bennett, A.
Superior Court of Pennsylvania, 2017
In the Interest of: Z.P., A Minor, Appeal of: L.P.
Superior Court of Pennsylvania, 2016
Betz v. Pneumo Abex LLC
44 A.3d 27 (Supreme Court of Pennsylvania, 2012)
Bodon-Soto v. Cohen
20 Pa. D. & C.5th 89 (Monroe County Court of Common Pleas, 2010)
Betz v. Pneumo Abex LLC
998 A.2d 962 (Superior Court of Pennsylvania, 2010)
Gannon v. United States
571 F. Supp. 2d 615 (E.D. Pennsylvania, 2007)
Hansen v. Wyeth Inc.
72 Pa. D. & C.4th 225 (Philadelphia County Court of Common Pleas, 2005)
Export Boxing & Crating Inc. v. Tech Met
62 Pa. D. & C.4th 45 (Alleghany County Court of Common Pleas, 2003)
Trach v. Fellin
817 A.2d 1102 (Superior Court of Pennsylvania, 2003)
Commonwealth v. Davies
811 A.2d 600 (Superior Court of Pennsylvania, 2002)
Commonwealth, Department of General Services v. United States Mineral Products Co.
809 A.2d 1000 (Commonwealth Court of Pennsylvania, 2002)
Callum v. Scott
58 Pa. D. & C.4th 1 (Lehigh County Court of Common Pleas, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
705 A.2d 1314, 1997 Pa. Super. LEXIS 3861, Counsel Stack Legal Research, https://law.counselstack.com/opinion/blum-ex-rel-blum-v-merrell-dow-pharmaceuticals-inc-pasuperct-1997.